The MARK-B™ COVID-19 test delivers results in 10 minutes on our unique MARK-B™ analyzer; making it more accurate than conventional RDT products. POCT with increased sensitivity is essential for the reliable detection of SARS-CoV-2 and enables immediate, effective treatment decisions.
The MARK-B™ COVID-19 Antigen S is CE marked, the Ab test will be followed soon.
MARK-B COVID-19
™
Difference-making innovation
MARK-B
COVID-19 Antigen S Test
™
Limit of Detection:
TCID 2.4 x10 per mL
50
-
Qualitative detection of SARS-CoV-2 spike proteins
-
Sensitivity 98.5% , Specificity 98.5 %
-
Fast results within 10 mins
-
Specimen : nasopharyngeal swab
-
CE marked.
MARK-B™
Quantitative immunoassay biosensor
to diagnosis cancer, cardiovascular diseases, sepsis, infectious diseases, thyroid disorders and so on.
Easy.
Quick.
Accurate
• Deliver lab-quality results
• Connected to anywhere
• Reduces the complexity
• Shorten time to diagnosis
Fully automated analysis
Once inserted into the instrument, the sample is separated into plasma by our patent technology.
In succession, the electrochemical analysis process begins.
No need for pre-processing
Self-contained consumable
Quick turnaround 10mins
.png)
Quantify precisely
by electrochemical method
MARK-B™ utilizes MESIA,
a patented technology of BBB inc.
Published Journal Paper
“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays for quantification of prostate-specific antigen in human serum”
- <Analytica Chimica Acta>, March, 2019
_ PhD. Hyundoo Hwang, Leader of BBB R&D Center
High expandability in test portfolio
*Not available for sale
*Scheduled to release in 2020
Connectivity!
Cloud server to communicate with MARK-B™ test results
POCT1-A2 protocol, HL7, FHIR® to communicate with DMS
Android based Analyzer software
Key specification
**Depends on the analyte
*** Optional